With pharma still struggling in Alzheimer’s, health tech companies want a swing

(By Katie Palmer for STAT)

In the wake of the first Alzheimer’s drug approval in nearly two decades, pharmaceutical companies have been reinvigorated in their effort to tackle the neurodegenerative disease. But as Aduhelm takes its first stuttering steps on the market, it’s clear pharma’s struggles are far from over — leaving an opening for a crop of software and device companies to take aim. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org